Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028384 | 0.84 | MAPT (0.47) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL5110176 | 0.82 | L3MBTL1 (0.46) | MAPTKDM4EMAPK1NPSR1L3MBTL1 | |
| SCHEMBL9024901 | 0.81 | GRM4 (0.46) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL3156531 | 0.80 | CYP2A6 (0.53) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL3095150 | 0.79 | TDO2 (0.41) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL7028379 | 0.79 | TDO2 (0.41) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL12349894 | 0.79 | GRM4 (0.43) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL5658498 | 0.79 | TDO2 (0.41) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL11962623 | 0.79 | TDO2 (0.49) | GAAMAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL9134518 | 0.79 | ALDH1A1 (0.49) | MAPTKDM4EMAPK1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023164234-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023062627-A1 | HERBICIDES AND USE THEREOF | PROJINI AGCHEM LTD (IL) | 2023-04-20 | — | — | WO | disclosed |
| EP-0581181-A1 | Process for the preparation of 4-dialkoxymetylpyrazoles | BASF Aktiengesellschaft (DE) | 1994-02-02 | — | — | EP | disclosed |
| US-5220028-A | Halogeno-4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0366328-B1 | PROCESS FOR PREPARING 4-METHYLPYRAZOLES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-5191087-A | PROCESS FOR THE SYNTHESIS OF 1,4-DISUBSTITUTED PYRAZOLES | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1993-03-02 | — | — | US | disclosed |
| EP-0526281-A1 | Process for the preparation of 1,4-substituted pyrazoles | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0366329-A1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366328-A1 | Process for preparing 4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
| CN-1031376-A | Pyrazolopyridine compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-03-01 | — | — | CN | disclosed |
| EP-0022078-B1 | PYRAZOLO-QUINOLINES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | GAA 3514/4885MAPT 3409/4885KDM4E 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.